Newly Published Data Reinforce Growing Body of Evidence Supporting Cidara Therapeutics’ Lead Antifungal CD101
December 14 2016 - 8:30AM
Business Wire
Data Showcase Compound’s Discovery through
Development and Potential to Expand Echinocandin Utility Across
Multiple Infectious-Disease Indications
Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data from preclinical and clinical studies
evaluating the company’s novel echinocandin antifungal CD101 appear
in the December 5 online issue of the journal Antimicrobial Agents
and Chemotherapy (AAC). These latest findings add to the growing
body of published scientific evidence that demonstrate the unique
attributes of Cidara’s lead antifungal drug candidate and showcase
the compound’s strategic discovery and rapid development.
“The publication of these latest findings in AAC further affirms
the clinical utility, safety and unique profile of CD101 across a
number of infectious-disease indications, including treatment and
prophylaxis of invasive fungal infections and treatment of
vulvovaginal candidiasis,” said Jeffrey Stein, Ph.D., president and
chief executive officer of Cidara. “We now have a compendium of
published data on CD101 that demonstrate the quality and scientific
rigor behind our antifungal drug development program. The discovery
and development of CD101 has unlocked a molecule, now in multiple
Phase 2 clinical trials, with differentiating properties and
utility far beyond that of currently approved echinocandins.”
In total, seven CD101 manuscripts were published during the
second half of 2016:
- Safety and Pharmacokinetics of CD101
IV, a Novel Echinocandin, in Healthy Adults, Antimicrobial Agents
and Chemotherapy, December 2016
- Structure-Activity Relationships of a
Series of Echinocandins and the Discovery of CD101, a Highly Stable
and Soluble Echinocandin with Distinctive Pharmacokinetic
Properties, Antimicrobial Agents and Chemotherapy, December
2016
- Preclinical Evaluation of the
Stability, Safety and Efficacy of CD101, a Novel Echinocandin,
Antimicrobial Agents and Chemotherapy, November 2016, Volume 60,
Issue 11
- Activity of a long-acting echinocandin,
CD101, determined using CLSI and EUCAST reference methods, against
Candida and Aspergillus spp., including echinocandin- and
azole-resistant isolates, Journal of Antimicrobial and
Chemotherapy, October 2016, Volume 71, Issue 10
- Characterization of in vitro resistance
development to the novel echinocandin, CD101, in Candida species,
Antimicrobial Agents and Chemotherapy, September 2016, Volume 60,
Issue 10
- CD101: a novel long-acting
echinocandin, Cell Microbiology, September 2016, Volume 18, Issue
9
- CD101, a novel echinocandin with
exceptional stability properties and enhanced aqueous solubility,
The Journal of Antibiotics, August 2016
Links to the full text of these publications are also available
on the Cidara website: https://www.cidara.com/publications/
About Invasive Fungal Infections
Fungal infections can carry a mortality rate of 35-50 percent,
higher than most bacterial infections. Approximately 97,000
Americans die from hospital-related fungal infections each year and
90 percent of these infections are caused by two common fungi,
Candida and Aspergillus. There is an urgent and growing need for
new therapeutic approaches to treat and prevent serious invasive
fungal infections.
About Vulvovaginal Candidiasis (VVC)
Vulvovaginal candidiasis (VVC) is a highly prevalent mucosal
fungal infection which impacts approximately 75 percent of women in
America. Many have moderate to severe symptoms and four to five
million are estimated to have recurrent infections. Current VVC
treatments have significant limitations and there have been no
novel therapies approved for the condition in more than 20 years.
Between 30 to 40 percent of women fail acute VVC therapy and 50
percent relapse with recurrent VVC within six months. Current
therapies are fungistatic, not fungicidal (meaning they inhibit the
growth of fungus but may not kill the fungus), and do not cover
non-albicans Candida strains.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on
developing new anti-infectives that have the potential to transform
the standard of care and save or improve patients’ lives. The
company is currently advancing its novel echinocandin antifungal,
CD101, through Phase 2 studies in two indications and developing
CD201, its bispecific antimicrobial immunotherapy, for the
treatment of multi-drug resistant bacterial infections. CD101 IV
has enhanced potency and is the only once-weekly therapy intended
for the treatment and prevention of life-threatening invasive
fungal infections. CD101 topical is the first and only agent of its
class being studied for the treatment and prevention of
vulvovaginal candidiasis (VVC), a prevalent mucosal infection.
CD201 is the first drug candidate selected from Cidara’s novel
Cloudbreak™ platform, the first immunotherapy discovery platform
designed specifically to create compounds that direct a patient's
immune cells to attack and eliminate bacterial, fungal or viral
pathogens. Cidara is headquartered in San Diego, California. For
more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effectiveness, safety, long-acting nature, anticipated human
dosing and other attributes of CD101, and its differentiation from
other therapies. Risks that contribute to the uncertain nature of
the forward-looking statements include: the success and timing of
Cidara’s preclinical studies and clinical trials; regulatory
developments in the United States and foreign countries; changes in
Cidara’s plans to develop and commercialize its product candidates;
Cidara’s ability to obtain additional financing; Cidara’s ability
to obtain and maintain intellectual property protection for its
product candidates; and the loss of key scientific or management
personnel. These and other risks and uncertainties are described
more fully in Cidara’s Form 10-Q most recently filed with the
United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Cidara undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161214005351/en/
INVESTORS:Westwicke Partners, LLCRobert H. Uhl,
858-356-5932Managing
Directorrobert.uhl@westwicke.comorMEDIA:Sam Brown
Inc.Christy Curran, 615-414-8668ChristyCurran@sambrown.com
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cidara Therapeutics (NASDAQ:CDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024